Journal
WORLD JOURNAL OF CLINICAL CASES
Volume 8, Issue 21, Pages 5320-5325Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.12998/wjcc.v8.i21.5320
Keywords
COVID-19; Nafamostat; Hyperkalemia; Disseminated intravascular coagulation; Respiratory insufficiency; Case report
Categories
Ask authors/readers for more resources
BACKGROUND Nafamostat mesylate (NM) may prove to be one of the key drugs effective against coronavirus disease 2019 (COVID-19) because of its anti-viral properties and the potential to manage coagulopathy. However, NM tends to increase serum potassium levels. CASE SUMMARY We observed hyperkalemia immediately after NM administration (200 mg/d) in four consecutive patients who were admitted to the Kanazawa University Hospital with severe COVID-19 pneumonia. Urinary potassium excretion decreased after NM administration in three patients who underwent urinalysis. CONCLUSION NM is likely to produce hyperkalemia in patients with COVID-19. Therefore, it is necessary to monitor serum potassium values closely after NM initiation in COVID-19 patients who need respiratory support.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available